XBIO Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of 12.65%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Electromed, Inc.'s return on equity of 18.89%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1718.18%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 25.31%. Given that Xenetic Biosciences, Inc. has higher upside potential than Electromed, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Electromed, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than Electromed, Inc.'s net income of $2.1M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 30.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.19x versus 3.83x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -36.3%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Myomo, Inc.'s return on equity of -68.35%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1718.18%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Xenetic Biosciences, Inc. has higher upside potential than Myomo, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Myomo, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.19x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of -862.39%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat VolitionRX Ltd.'s return on equity of --.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1718.18%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 773.02%. Given that Xenetic Biosciences, Inc. has higher upside potential than VolitionRX Ltd., analysts believe Xenetic Biosciences, Inc. is more attractive than VolitionRX Ltd..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Xenetic Biosciences, Inc.'s net income of -$509.9K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.19x versus 17.27x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -49.65% compared to Xenetic Biosciences, Inc.'s net margin of 3.93%. Xenetic Biosciences, Inc.'s return on equity of -59.39% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Xenetic Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 1718.18%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 92.8%. Given that Xenetic Biosciences, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Xenetic Biosciences, Inc. is more attractive than Xtant Medical Holdings, Inc..

Xenetic Biosciences, Inc. has a beta of 2.398, which suggesting that the stock is 139.837% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Xenetic Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xenetic Biosciences, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Xenetic Biosciences, Inc. quarterly revenues are $1M, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Xenetic Biosciences, Inc.'s net income of -$509.9K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Xenetic Biosciences, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 76.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xenetic Biosciences, Inc. is 1.19x versus 0.85x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.